MedTrace Logo

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03986086 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-03-20

No results posted yet for this study

Summary

The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic stem cell transplant.

Conditions

  • Hematologic Malignancy

Interventions

DRUG

MPH966

RP2D tablet

DRUG

Placebo

MPH966 placebo table

Sponsors & Collaborators

  • Mereo BioPharma

    collaborator INDUSTRY

  • National Center for Advancing Translational Sciences (NCATS)

    collaborator NIH

  • Nelson Chao

    lead OTHER

Principal Investigators

  • Anthony Sung, MD · Duke University Health System (DUHS)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03986086 on ClinicalTrials.gov